Your browser doesn't support javascript.
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
Chemaitelly, Hiam; Tang, Patrick; Hasan, Mohammad R; AlMukdad, Sawsan; Yassine, Hadi M; Benslimane, Fatiha M; Al Khatib, Hebah A; Coyle, Peter; Ayoub, Houssein H; Al Kanaani, Zaina; Al Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar H; Latif, Ali N; Shaik, Riyazuddin M; Abdul Rahim, Hanan F; Nasrallah, Gheyath K; Al Kuwari, Mohamed G; Al Romaihi, Hamad E; Butt, Adeel A; Al-Thani, Mohamed H; Al Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J.
  • Chemaitelly H; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Tang P; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Hasan MR; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • AlMukdad S; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Yassine HM; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Benslimane FM; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Al Khatib HA; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Coyle P; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Ayoub HH; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Al Kanaani Z; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Al Kuwari E; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Jeremijenko A; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Kaleeckal AH; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Latif AN; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Shaik RM; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Abdul Rahim HF; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Nasrallah GK; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Al Kuwari MG; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Al Romaihi HE; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Butt AA; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Al-Thani MH; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Al Khal A; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Bertollini R; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
  • Abu-Raddad LJ; From the Infectious Disease Epidemiology Group (H.C., S.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., L.J.A.-R.), Weill Cornell Medicine-Qatar, Cornell University
N Engl J Med ; 385(24): e83, 2021 12 09.
Article in English | MEDLINE | ID: covidwho-1454879
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear.

METHODS:

We used a matched test-negative, case-control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of Covid-19, from January 1 to September 5, 2021.

RESULTS:

Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2 weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in the first month after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating after the fourth month to reach approximately 20% in months 5 through 7 after the second dose. Effectiveness against symptomatic infection was higher than effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19 increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at approximately this level for 6 months.

CONCLUSIONS:

BNT162b2-induced protection against SARS-CoV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine-Qatar and others.).
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 / Vaccine Efficacy / BNT162 Vaccine Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: N Engl J Med Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 / Vaccine Efficacy / BNT162 Vaccine Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: N Engl J Med Year: 2021 Document Type: Article